CRISPR–Cas technologies provide a modular, programmable platform for sequence-specific targeting of DNA or RNA and have advanced from experimental molecular biology tools to clinical translation. This...

Artificial intelligence promises rapid and polite feedback on papers — but we must first review the reviewer.

ALT: a bald man in a plaid shirt and vest

Success Story Didier Trono While other countries are pressing ahead with the Genome of Europe, Switzerland is still hesitating. A huge mistake, says Didier Trono from the Genome Center in Geneva “I do...

The ERC Synergy Grants 2026 call closed for applications on 5 November 2025. These are the preliminary data on the submitted proposals:

RNA-guided nucleases enable DNA editing and offer promise for treating genetic diseases, particularly when used for precise sequence replacement. However, many of the most effective enzymes, such as S...

Thanks to CRISPR/Cas technology, researchers can precisely edit genetic material to treat hereditary diseases. To achieve this, they need to identify undesirable cuts in the genome at an early junctur...

Genome editing outcomes are governed by DNA repair pathways that vary with cell type and state. We developed scOUT-seq (single-cell Outcomes Using Transcript sequencing), a scalable approach that join...

bioRxiv - the preprint server for biology, operated by Cold Spring Harbor Laboratory, a research and educational institution

ALT: a man wearing an orange jacket with the number 22573 on it holds a candy bar

SCF–FBXO31 scans proteins for C-terminal amidation and marks them for subsequent proteasomal degradation.